1. That the user account issued to me is a unique code that gives me authorized access to the systems and applications of the institution licensing the same ("Licensee"), the user account information and unique user code are not to be shared or disclosed with any unauthorized persons and I will take the appropriate steps to protect this information.

2. That any information accessed is strictly confidential and to be used only in the performance of my necessary duties,

3. to abide by all policies and procedures adopted by Licensee as well as all current federal and state laws governing information technology and patient confidentiality and such access, including the Health Insurance Portability and Accountability Act (known as "HIPAA"), which governs the privacy and security of protected health information, and to use appropriate safeguards to protect confidential patient information and make no disclosures except as required by law or for the purposes of my necessary duties. I understand that Caris encrypts email messages, some of which contain PHI, as a matter of policy. Caris strongly encourages the use of encryption by all licensed users of Caris Molecular Tumor Board("Licensees"). I understand that if I am unwilling or unable to accept or send encrypted emails, Caris encourages me to use safeguards such as avoiding the use of PHI or using alternative means of communication. Licensees are encouraged to contact Caris at (888) 979-8669 should they have questions or want to discuss matters of security and additional measures for the protection of PHI.

4. That if at any time I may feel that the confidentiality of my security user account/password has been compromised, I will immediately contact the appropriate Compliance Officer at my Licensee institution and participate in investigating the circumstances around the compromise, and

5. that if I abuse access privileges, I may be subject to disciplinary action including but not limited to termination, civil penalties and criminal penalties.

6. The downloading of discrete patient information from this application is subject to the terms and conditions of the Caris Molecular Tumor Board including but not limited to:

      • Information is strictly confidential and to be used only in the performance of my necessary duties. Downloading the information with the intent to sell, transfer, or commercialize any information obtained from Caris Molecular Tumor Board is prohibited.

      • Agreement to abide by all policies and procedures adopted by Licensee as well as all current federal and state laws governing information technology and patient confidentiality and such access, including but not limited to HIPAA, CCPA, and other related state privacy laws

Caris Molecular Tumor Board is subject to Caris' intellectual property. Patent www.carislifesciences.com/ip.